InspireMD (NSPR) Research & Development (2010 - 2026)

InspireMD has reported Research & Development for 17 years, with the latest figure at $5.2 million in Q2 2026.

• On a quarterly basis, Research & Development rose 25.14% year-over-year to $5.2 million in Q2 2026; TTM through Jun 2026 was $19.8 million, a 25.12% increase from a year earlier, with the FY2025 full-year figure at $16.6 million, up 21.41% from the prior year.
• Research & Development was $5.2 million for Q2 2026 at InspireMD, up from $5.2 million in the prior quarter.
• The five-year high for Research & Development was $5.2 million in Q2 2026, with the low at $1.7 million in Q1 2022.
• Average Research & Development over 5 years is $3.2 million, with a median of $3.0 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2023: Research & Development jumped 100.24% in 2022, then declined 3.06% in 2023.
• Over 5 years, Research & Development stood at $2.0 million in 2022, then grew by 1.09% to $2.0 million in 2023, then jumped by 81.47% to $3.7 million in 2024, then jumped by 36.07% to $5.0 million in 2025, then grew by 3.9% to $5.2 million in 2026.
• The last three Research & Development figures came in at $5.2 million (Q2 2026), $5.2 million (Q1 2026), and $5.0 million (Q4 2025), per Business Quant data.